Trial · NCT03285477
Results by group126
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 126
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions | Placebo | 5 | percentage of participants | ||
| Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions | KX2-391 Ointment 1% | 44 | percentage of participants | ||
| Percentage of Participants With Partial Clearance Rate of Actinic Keratosis Lesions at Day 57 | Placebo | 16 | percentage of participants | ||
| Percentage of Participants With Partial Clearance Rate of Actinic Keratosis Lesions at Day 57 | KX2-391 Ointment 1% | 68 | percentage of participants | ||
| Overall Change From Baseline in Actinic Keratosis Lesion Counts at Days 8, 15, 29 and 57 | Placebo | Day 8 | 0.0 | Full Range -7 to 3 | lesion count |
| Overall Change From Baseline in Actinic Keratosis Lesion Counts at Days 8, 15, 29 and 57 | KX2-391 Ointment 1% | Day 8 | -1.0 | Full Range -8 to 4 | lesion count |
| Overall Change From Baseline in Actinic Keratosis Lesion Counts at Days 8, 15, 29 and 57 | Placebo | Day 15 | 0.0 | Full Range -7 to 2 | lesion count |
| Overall Change From Baseline in Actinic Keratosis Lesion Counts at Days 8, 15, 29 and 57 | KX2-391 Ointment 1% | Day 15 | -4.0 | Full Range -8 to 4 | lesion count |
| Overall Change From Baseline in Actinic Keratosis Lesion Counts at Days 8, 15, 29 and 57 | Placebo | Day 29 | -1.0 | Full Range -7 to 4 | lesion count |
| Overall Change From Baseline in Actinic Keratosis Lesion Counts at Days 8, 15, 29 and 57 | KX2-391 Ointment 1% | Day 29 | -4 | Full Range -8 to 1 | lesion count |
| Overall Change From Baseline in Actinic Keratosis Lesion Counts at Days 8, 15, 29 and 57 | Placebo | Day 57 | -1.0 | Full Range -7 to 5 | lesion count |
| Overall Change From Baseline in Actinic Keratosis Lesion Counts at Days 8, 15, 29 and 57 | KX2-391 Ointment 1% | Day 57 | -5.0 | Full Range -8 to 0 | lesion count |
| Percentage of Participants With Recurrence of Actinic Keratosis Lesions Who Achieved Complete Clearance at Day 57 | KX2-391 Ointment 1% | 3 Months Post-Day 57 | 33 | percentage of participants | |
| Percentage of Participants With Recurrence of Actinic Keratosis Lesions Who Achieved Complete Clearance at Day 57 | KX2-391 Ointment 1% | 6 Months Post-Day 57 | 30 | percentage of participants | |
| Percentage of Participants With Recurrence of Actinic Keratosis Lesions Who Achieved Complete Clearance at Day 57 | KX2-391 Ointment 1% | 9 Months Post-Day 57 | 33 | percentage of participants | |
| Percentage of Participants With Recurrence of Actinic Keratosis Lesions Who Achieved Complete Clearance at Day 57 | KX2-391 Ointment 1% | 12 months Post-Day 57 | 18 | percentage of participants | |
| Number of Participants With Maximal Post Baseline Local Skin Reaction (LSR) | Placebo | Erythema-Grade 0 | 81 | Participants | |
| Number of Participants With Maximal Post Baseline Local Skin Reaction (LSR) | KX2-391 Ointment 1% | Erythema-Grade 0 | 6 | Participants | |
| Number of Participants With Maximal Post Baseline Local Skin Reaction (LSR) | Placebo | Erythema-Grade 1 | 84 | Participants | |
| Number of Participants With Maximal Post Baseline Local Skin Reaction (LSR) | KX2-391 Ointment 1% | Erythema-Grade 1 | 48 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03285477/results